{"product_id":"krbp-vrio-analysis","title":"Kiromic BioPharma, Inc. (KRBP): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlock the secrets to Kiromic BioPharma, Inc. (KRBP)'s sustained success by diving into this essential VRIO Analysis. We distill the core findings - Value, Rarity, Inimitability, and Organization - into the critical summary found in \u0026amp;O4\u0026amp;, revealing exactly where this business's competitive edge lies. Read on to grasp the strategic implications immediately.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eKiromic BioPharma, Inc. (KRBP) - VRIO Analysis: \u003cstrong\u003e1. DIAMOND® Artificial Intelligence Platform\u003c\/strong\u003e\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at the core technology of Kiromic BioPharma, the DIAMOND® Artificial Intelligence Platform, right as the company faced a major operational hurdle with its Chapter 7 bankruptcy filing in April 2025. Honestly, the platform's potential value is what drove the initial investment, but the company’s inability to secure funding beyond March 2025 overshadows its current competitive standing.\u003c\/p\u003e\n\n\u003ch3\u003eVRIO Assessment: DIAMOND® Artificial Intelligence Platform\u003c\/h3\u003e\n\u003cp\u003eHere’s the quick math on how this proprietary engine stacks up against the VRIO criteria, keeping in mind the context of the company’s recent financial distress.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eVRIO Dimension\u003c\/th\u003e\n    \u003cth\u003eAssessment\u003c\/th\u003e\n    \u003cth\u003eKey Supporting Data\/Context\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eValue (V)\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eHigh Potential Value\u003c\/td\u003e\n    \u003ctd\u003eDesigned to dramatically compress the man-years and billions of drug development dollars required for target identification.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eRarity (R)\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eLikely Rare\u003c\/td\u003e\n    \u003ctd\u003eProprietary, integrated AI platform specifically for target discovery in immuno-oncology is rare for a company of its size.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eImitability (I)\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eCostly to Imitate\u003c\/td\u003e\n    \u003ctd\u003eReplication requires massive, curated datasets and specialized data science talent.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eOrganization (O)\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eCurrently Impaired\u003c\/td\u003e\n    \u003ctd\u003eThe company filed for Chapter 7 bankruptcy in March 2025, meaning the organization is no longer structured to exploit the resource.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003ePotential for Sustained Advantage (Currently Lost)\u003c\/td\u003e\n    \u003ctd\u003eAdvantage is contingent on the platform generating clinically validated targets and the company being operational to commercialize them.\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eWhat this estimate hides is that while the technology itself might be valuable, the organization - Kiromic BioPharma - is no longer functioning as a going concern, having filed for bankruptcy. This means the resource is currently stranded.\u003c\/p\u003e\n\n\u003ch4\u003eValue (V)\u003c\/h4\u003e\n\u003cp\u003eThe platform’s value proposition is clear: speed and cost reduction in drug discovery. In the fiscal year ended December 31, 2024, Kiromic BioPharma reported Research and Development expenses of \u003cstrong\u003e$6.9 million\u003c\/strong\u003e, indicating ongoing investment in its pipeline, which is driven by this AI. If the platform successfully identifies a novel target that leads to a drug, the value generated would be immense, easily justifying the R\u0026amp;D spend.\u003c\/p\u003e\n\n\u003ch4\u003eRarity (R)\u003c\/h4\u003e\n\u003cp\u003eThe proprietary nature of the DIAMOND® platform makes it rare. As of early 2022, the DIAMOND® AI 2.0 Platform included nearly \u003cstrong\u003eTwo Billion Data Points\u003c\/strong\u003e, a significant asset for an immuno-oncology focus. For a smaller biotech, having such a large, curated dataset integrated into a proprietary predictive engine is not common; most peers rely on external data or less integrated systems.\u003c\/p\u003e\n\n\u003ch4\u003eImitability (I)\u003c\/h4\u003e\n\u003cp\u003eIt’s defintely hard to copy. Replicating the predictive power requires not just the software, but the unique, massive, and likely proprietary datasets it was trained on, plus the specialized data science talent to maintain and enhance it. This creates a high barrier to entry for competitors trying to build a similar tool from scratch.\u003c\/p\u003e\n\n\u003ch4\u003eOrganization (O)\u003c\/h4\u003e\n\u003cp\u003eThis is where the analysis hits a wall. While the company was organized around using the platform to drive its pipeline - evidenced by the increased clinical trial expenses leading to a \u003cstrong\u003e$26.9 million\u003c\/strong\u003e net loss for FY2024 - the structure collapsed. The Chapter 7 filing in 2025 means the organization is no longer capable of effectively deploying the platform to capture value.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAsset sale process initiated in April 2025.\u003c\/li\u003e\n\u003cli\u003eCash resources were insufficient beyond March 2025.\u003c\/li\u003e\n\u003cli\u003eFocus shifted from development to survival.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe competitive advantage hinges on organization; without it, the advantage is theoretical.\u003c\/p\u003e\n\n\u003cp\u003eFinance: Review the asset sale documentation to determine the residual value assigned to the DIAMOND® IP by the buyer by next Tuesday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eKiromic BioPharma, Inc. (KRBP) - VRIO Analysis: \u003cstrong\u003e2. Allogeneic Gamma Delta T-cell Therapy Platform (Procel®\/Isis®)\u003c\/strong\u003e\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe platform, exemplified by Deltacel™ (KB-GDT-01), is an allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy candidate, designed to address scalability and cost associated with autologous treatments. Deltacel is the leading candidate in the GDT platform.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe platform is based on GDT cells targeting solid tumors, with an initial clinical focus on Non-Small Cell Lung Cancer (NSCLC), which accounts for approximately 80% to 85% of all lung cancer cases. Investigational New Drug (IND) applications for ALEXIS-PRO-1 (Procel™) and ALEXIS-ISO-1 (Isocel™) were filed with the FDA in May 2021.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDevelopment costs reflect the complexity of the platform. Research and development expenses for the fiscal year ended December 31, 2024, were $6.9 million, slightly decreased from $7.0 million the previous year, with a focus on Deltacel development. Clinical trial expenses specifically rose to $8.1 million in FY 2024, up from $2.7 million the prior year, due to the activation of the Deltacel-01 clinical trial. The company reported a net loss of $26.9 million for the year ended December 31, 2024.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe platform is central to product strategy, with Deltacel currently in a Phase 1 clinical trial. Key organizational milestones and trial progress include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePart 1 enrollment of the Deltacel-01 trial was completed as of August 2024.\u003c\/li\u003e\n\u003cli\u003eThe company is on track to initiate Part 2 of Deltacel-01 in September (2024).\u003c\/li\u003e\n\u003cli\u003eAs of February 7, 2025, 4 of 9 additional patients were enrolled in the expansion phase, with enrollment expected to be completed by March 2025.\u003c\/li\u003e\n\u003cli\u003eThe FDA granted Fast-Track Designation for Deltacel in August 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe clinical performance data for Deltacel-01 provides quantitative support for the platform's potential:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003ePatient 1 Data (as of Oct 2024)\u003c\/td\u003e\n\u003ctd\u003ePatients 1-5 Average (as of Aug 2024)\u003c\/td\u003e\n\u003ctd\u003ePatient 4 Data (as of Jan 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProgression-Free Survival (PFS)\u003c\/td\u003e\n\u003ctd\u003e10 months\u003c\/td\u003e\n\u003ctd\u003e4.8 months (Range: 2 to 8 months)\u003c\/td\u003e\n\u003ctd\u003e10 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTumor Response\u003c\/td\u003e\n\u003ctd\u003eApprox. 27% reduction in tumor size at 10 months\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003ePartial Response (\u0026gt;= 30% decrease) registered at 8 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe Fast-Track Designation from the FDA in August 2024 may expedite development and review. The platform's ability to generate durable responses, such as the 10-month PFS reported for Patient 1 and Patient 4, suggests a potential for sustained benefit over standard therapies for patients who have failed prior treatments.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eKiromic BioPharma, Inc. (KRBP) - VRIO Analysis: \u003cstrong\u003e3. Deltacel Product Candidate Momentum\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e It is the most advanced asset, potentially validating the entire technology platform through clinical success.\u003c\/p\u003e\n\u003cp\u003eClinical efficacy data points include a 32% Decrease in Tumor Volume at Eight Months post-treatment for Patient 4, and 10-Month Progression-Free Survival reported for the same patient. Interim safety and efficacy data from Part 1 of the Deltacel-01 trial demonstrated a Progression-Free Survival (PFS) of 4.8 months (range, 2-8) among 5 evaluable patients. Patient 2 previously showed a complete response in their brain metastasis.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e The specific construct and target profile of Deltacel is unique within their pipeline.\u003c\/p\u003e\n\u003cp\u003eDeltacel is an allogeneic product consisting of unmodified, donor-derived gamma delta T cells. The initial clinical focus is on Non-Small Cell Lung Cancer (NSCLC), which represents about 80% to 85% of all lung cancer cases.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low for the asset itself, but high for the clinical data once it's public.\u003c\/p\u003e\n\u003cp\u003eThe proprietary DIAMOND® AI platform is used for target discovery, which is intended to compress development time and cost.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes, the organization is heavily focused on advancing this through the expansion phase and preparing for pivotal trial design feedback from the FDA around June 2025.\u003c\/p\u003e\n\u003cp\u003eOrganizational focus is reflected in financial allocations and regulatory milestones:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eClinical trial expenses for the year ending 2024 rose to $8.1 million from $2.7 million due to the activation of the Deltacel-01 clinical trial.\u003c\/li\u003e\n\u003cli\u003eResearch and development expenses for the nine months ended September 30, 2024, were $4,228,000 for the quarter, an increase from $2,677,000 in the same quarter the previous year.\u003c\/li\u003e\n\u003cli\u003eThe company has 44 full-time employees.\u003c\/li\u003e\n\u003cli\u003eThe FDA granted Fast Track Designation in August 2024.\u003c\/li\u003e\n\u003cli\u003eThe company acknowledged the need for additional funding to support operations beyond March 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe status of the Deltacel-01 Phase 1 trial:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\/Status\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIndication Focus\u003c\/td\u003e\n\u003ctd\u003eStage 4 metastatic NSCLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial Phase\u003c\/td\u003e\n\u003ctd\u003ePhase 1 (Deltacel-01)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA Designation\u003c\/td\u003e\n\u003ctd\u003eFast Track (August 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated Study Completion Date\u003c\/td\u003e\n\u003ctd\u003eJanuary 2027\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. Its value is entirely dependent on positive clinical data readouts.\u003c\/p\u003e\n\u003cp\u003eFinancial context as of late 2024:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Metric\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss (Year 2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$26.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Cash Equivalents (Sep 30, 2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3,056,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancing Raised (2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$18.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Capitalization (2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$23.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eKiromic BioPharma, Inc. (KRBP) - VRIO Analysis: \u003cstrong\u003e4. Cancer Stem Cell Targeting Expertise\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003eTargeting the root cause of cancer recurrence offers a potentially curative, rather than just palliative, value proposition.\u003c\/p\u003e\n\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eTargeting the root cause of cancer recurrence offers a potentially curative, rather than just palliative, value proposition.\u003c\/p\u003e\n\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eThis specific strategic focus within cell therapy is not common; many focus on bulk tumor antigens.\u003c\/p\u003e\n\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eModerate. It requires deep biological understanding that takes years to build.\u003c\/p\u003e\n\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eYes, this is a core tenet of their mission and technology application.\u003c\/p\u003e\n\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eSustained, as it represents a fundamental, hard-to-shift strategic direction.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric Category\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003cth\u003eAssociated Figure\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Trial Focus (NSCLC)\u003c\/td\u003e\n\u003ctd\u003ePrevalence of NSCLC in Lung Cancer\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e80% to 85%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline Focus (Solid Tumors)\u003c\/td\u003e\n\u003ctd\u003ePrevalence of Solid Tumors\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e90%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDeltacel-01 Efficacy (Patient #4)\u003c\/td\u003e\n\u003ctd\u003eTumor Volume Decrease (8-month follow-up)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e32%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDeltacel-01 Efficacy (Patient #1)\u003c\/td\u003e\n\u003ctd\u003eProgression-Free Survival (PFS)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e11 months\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial - R\u0026amp;D Expenses (FY 2024)\u003c\/td\u003e\n\u003ctd\u003eResearch and Development Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial - Clinical Costs (FY 2024)\u003c\/td\u003e\n\u003ctd\u003eClinical Trials Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial - Loss (FY 2024)\u003c\/td\u003e\n\u003ctd\u003eNet Loss for the Year\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$26.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Context\u003c\/td\u003e\n\u003ctd\u003eGlobal Cancer Cell Therapy Market Estimate (2027)\u003c\/td\u003e\n\u003ctd\u003eExceed $33 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompany Size\u003c\/td\u003e\n\u003ctd\u003eNumber of Employees\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e31\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eThe Deltacel-01 trial evaluates an allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy for stage 4 metastatic non-small cell lung cancer (NSCLC) (NCT06069570).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eThe trial involves two intravenous infusions of Deltacel™ with four courses of low-dose, localized radiation over a 10-day period.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eThe company's DIAMOND® AI platform is used for target discovery, aiming to compress development time and cost.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eGross proceeds from a June 2021 public offering were $40 million at $5.00 per share.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eKiromic BioPharma, Inc. (KRBP) - VRIO Analysis: \u003cstrong\u003e5. Intellectual Property Estate\u003c\/strong\u003e\n\u003c\/h2\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eThe DIAMOND platform, an artificial intelligence bioinformatic approach, is utilized for identifying novel surface tumor targets for T cells and B cells. The platform leverages big data science to compress development timelines and costs. The Company has a proprietary target discovery engine called 'Diamond.'\u003c\/p\u003e\n\u003cp\u003eThe DIAMOND data mining tools sift through billions of data points to identify rare cancer-specific immunotherapy targets. The database contains approximately 2 billion data points, covering 38 types of cancer and 47 types of normal human tissue.\u003c\/p\u003e\n\u003cp\u003eR\u0026amp;D expenses for the fiscal year ended December 31, 2024, were $6.9 million. For the nine months ended September 30, 2024, cash used in operating activities was $15,810,000.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eIP\/Platform Metric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eReporting Period\/Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDIAMOND Database Data Points\u003c\/td\u003e\n\u003ctd\u003eApproximately 2 billion\u003c\/td\u003e\n\u003ctd\u003eAs of Q3 2021\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCancer Types Covered\u003c\/td\u003e\n\u003ctd\u003e38\u003c\/td\u003e\n\u003ctd\u003eCurrent\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNormal Human Tissue Types Covered\u003c\/td\u003e\n\u003ctd\u003e47\u003c\/td\u003e\n\u003ctd\u003eCurrent\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses\u003c\/td\u003e\n\u003ctd\u003e$6.9 million\u003c\/td\u003e\n\u003ctd\u003eFiscal Year Ended December 31, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDeltacel-01 Trial Status\u003c\/td\u003e\n\u003ctd\u003ePhase 1 clinical trial\u003c\/td\u003e\n\u003ctd\u003eCurrent\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eThe breadth of the IP estate covering AI-discovered targets is a key differentiator within the industry standard. The Company has a license agreement with Longwood University and a research and development collaboration agreement with Molipharma, S.R.L.\u003c\/p\u003e\n\u003cp\u003eThe Company received Fast-Track Designation from the FDA for Deltacel in August 2024.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe DIAMOND AI® platform is described as where data science meets target identification to dramatically compress the years and hundreds of millions of dollars required to develop a live drug.\u003c\/li\u003e\n\u003cli\u003eA patent application for 'Platform for the identification of tumor-associated cancer\/testes antigens' was published on October 26, 2017.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003ePatents, when granted and in force, represent legally protected barriers to entry against direct imitation of specific compositions or methods. The Company acknowledges that its compositions and methods may not be patentable.\u003c\/p\u003e\n\u003cp\u003eThe Company had 44 Fulltime Employees as of the latest data.\u003c\/p\u003e\n\u003cp\u003eNet loss for the fiscal year ended December 31, 2024, was $26.9 million.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eThe R\u0026amp;D efforts are structured to feed the IP portfolio, evidenced by the development of the DIAMOND platform and subsequent product candidates like Deltacel, Isocel, and Procel.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe Company submitted an IND protocol amendment to the FDA on October 1, 2024, which became effective on November 1, 2024.\u003c\/li\u003e\n\u003cli\u003eThe Company uplisted to the OTCQB® Venture Market effective November 17, 2023.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eSustained competitive advantage is contingent upon the continued enforceability and scope of the patent portfolio surrounding the DIAMOND platform and its resulting therapeutic candidates. The Company reported a year-to-date price change of 14.44% as of the latest data.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eKiromic BioPharma, Inc. (KRBP) - VRIO Analysis: \u003cstrong\u003e6. Clinical Trial Execution Capability\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The ability to successfully manage complex cell therapy trials, like the Deltacel-01 expansion phase, which they expected to complete enrollment by March 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Many small biotechs struggle with site activation and patient enrollment.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. It relies on established relationships with clinical sites and experienced CROs (Contract Research Organizations).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes, evidenced by their progression from Phase 1 to planning for a pivotal Phase 2 trial.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. It’s an operational skill that can be hired or outsourced.\u003c\/p\u003e\n\u003cp\u003eThe execution capability is demonstrated by the progression of the Deltacel-01 trial, which received \u003cstrong\u003eFast-Track Designation\u003c\/strong\u003e from the FDA in \u003cstrong\u003eAugust 2024\u003c\/strong\u003e. The trial, evaluating Deltacel™ in combination with low-dose radiotherapy for Stage 4 metastatic non-small cell lung cancer, has shown early efficacy signals.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\/Status\u003c\/th\u003e\n\u003cth\u003eDate\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated Total Enrollment\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e48\u003c\/strong\u003e patients\u003c\/td\u003e\n\u003ctd\u003eNCT06069570 Trial Estimate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpansion Phase (Part 2) Enrollment Target\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003enine\u003c\/strong\u003e patients\u003c\/td\u003e\n\u003ctd\u003eFollowing SMC recommendation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Trial Expenses (Year Ended Dec 31, 2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp from \u003cstrong\u003e$2.7 million\u003c\/strong\u003e previous year due to trial activation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients with Partial Response (PR) Reported\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eTwo\u003c\/strong\u003e patients\u003c\/td\u003e\n\u003ctd\u003eAs of January 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLongest Progression-Free Survival (PFS) Reported\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e10 months\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFor Patient 4, as of January 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLargest Tumor Volume Decrease Reported\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e33.33%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFor Patient 1 at 12-month follow-up\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe progression of the trial involved activating multiple sites, with a fifth site expected to be activated on \u003cstrong\u003eAugust 30, 2024\u003c\/strong\u003e. At least \u003cstrong\u003eseven\u003c\/strong\u003e patients were reported as enrolled by \u003cstrong\u003eJanuary 2025\u003c\/strong\u003e. The financial commitment to this execution is substantial, with clinical trial expenses rising to \u003cstrong\u003e$8.1 million\u003c\/strong\u003e for the year ended December 31, 2024.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe trial is being conducted across multiple sites, including \u003cstrong\u003eBeverly Hills Cancer Center (BHCC)\u003c\/strong\u003e and \u003cstrong\u003eVirginia Oncology Associates, PC\u003c\/strong\u003e (the second activated site).\u003c\/li\u003e\n\u003cli\u003eThe Safety Monitoring Committee (SMC) unanimously recommended proceeding with the expansion phase after reviewing safety data from the first two cohorts, observing \u003cstrong\u003eno dose-limiting toxicities (DLTs)\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash used in operating activities for the nine months ended \u003cstrong\u003eSeptember 30, 2024\u003c\/strong\u003e, was \u003cstrong\u003e$15,810,000\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eKiromic BioPharma, Inc. (KRBP) - VRIO Analysis: \u003cstrong\u003e7. Recent Financing Success\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eProvided necessary runway to fund operations and clinical expenses, raising \u003cstrong\u003e$18.4 million\u003c\/strong\u003e via convertible notes as of the February 2025 10-K filing.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eAmount\u003c\/th\u003e\n\u003cth\u003ePeriod\/Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Cash Provided by Financing Activities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$18.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYear Ended December 31, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Cash Provided by Financing Activities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$24.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYear Ended December 31, 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConvertible Notes Issued (2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$19.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYear Ended December 31, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon-Cash Issuance of Convertible Notes\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYear Ended December 31, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eLow. Most clinical-stage companies must raise capital regularly.\u003c\/p\u003e\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eLow. It’s a function of market sentiment and investor appetite.\u003c\/p\u003e\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eYes, the CFO and leadership team successfully executed this financing to support operations.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNet Loss for the Year Ended December 31, 2024: \u003cstrong\u003e$26.9 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eNet Loss for the Year Ended December 31, 2023: \u003cstrong\u003e$20.9 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eClinical Trial Expenses (2024): \u003cstrong\u003e$8.1 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eCash Resources Insufficient Beyond: \u003cstrong\u003eMarch 2025\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eTemporary. This is a necessary, recurring activity, not a source of lasting advantage.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eKiromic BioPharma, Inc. (KRBP) - VRIO Analysis: \u003cstrong\u003e8. Integrated Discovery to Manufacturing Focus\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Developing scalable manufacturing processes in-house reduces reliance on third-party CDMOs (Contract Development and Manufacturing Organizations) and potentially lowers future Cost of Goods Sold (COGS).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Many early-stage firms outsource all manufacturing development.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. Developing proprietary, scalable cell therapy manufacturing is technically difficult and capital-intensive.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes, the company explicitly focuses on developing these scalable processes.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, if their internal processes prove significantly more efficient or higher-yield than outsourced options.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric Category\u003c\/th\u003e\n\u003cth\u003eSpecific Data Point\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eReference Period\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntegration Status\u003c\/td\u003e\n\u003ctd\u003eCompany Description\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eFully integrated\u003c\/strong\u003e biotherapeutics company\u003c\/td\u003e\n\u003ctd\u003eAs of July 2022 milestone announcement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing Footprint\u003c\/td\u003e\n\u003ctd\u003eExpanded cGMP Facility Size\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e34,000-square-foot\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFacility completion milestone\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFacility Components\u003c\/td\u003e\n\u003ctd\u003eKey Internal Labs\u003c\/td\u003e\n\u003ctd\u003eFlexible cellular therapy suites, viral vector suites, dedicated cGMP microbiology lab, dedicated cGMP QC lab\u003c\/td\u003e\n\u003ctd\u003eFacility details\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Impact (R\u0026amp;D)\u003c\/td\u003e\n\u003ctd\u003eResearch and Development Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4,228,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQuarter ended September 30, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Impact (R\u0026amp;D)\u003c\/td\u003e\n\u003ctd\u003eResearch and Development Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFiscal year ended December 31, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperational Spending\u003c\/td\u003e\n\u003ctd\u003eCash Used in Operating Activities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$15,810,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNine months ended September 30, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe organizational commitment to internal development is evidenced by specific capital investments and operational structure:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCompletion of an expanded cGMP \u003cstrong\u003e34,000-square-foot\u003c\/strong\u003e facility to support the cell therapy oncology pipeline.\u003c\/li\u003e\n\u003cli\u003eThe facility houses specialized areas including flexible cellular therapy and viral vector suites, supporting in-house process scale-up.\u003c\/li\u003e\n\u003cli\u003eResearch and development expenses for the nine months ended September 30, 2024, were reported alongside outsourced research and development expenses, indicating a mixed but significant R\u0026amp;D spend of \u003cstrong\u003e$4,228,000\u003c\/strong\u003e for the quarter ending September 30, 2024.\u003c\/li\u003e\n\u003cli\u003eThe company's annual Research and Development expenses were \u003cstrong\u003e$6.9 million\u003c\/strong\u003e for the fiscal year ended December 31, 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eKiromic BioPharma, Inc. (KRBP) - VRIO Analysis: \u003cstrong\u003e9. Experienced Leadership in Immuno-Oncology\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides strategic direction and credibility to attract talent, partners, and investors, led by figures like CEO Maurizio Chiriva-Internati, MD, who has served as Chairman and Chief Executive Officer since February 2018.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. The specific combination of clinical and business acumen is not common.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. Key individuals can leave, but the institutional knowledge remains for a time.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes, the leadership team is in place and driving the strategy.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. Key personnel retention is always a risk in this sector.\u003c\/p\u003e\n\u003cp\u003eThe VRIO assessment components are summarized below:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eValue:\u003c\/strong\u003e Strategic direction provided by leadership.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate due to specialized acumen.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate risk associated with key personnel departure.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOrganization:\u003c\/strong\u003e Structure is currently in place to execute strategy.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Assessed as Temporary.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinance: 13-Week Cash Flow Projection Incorporating Known Burn Rate and Capital Raised.\u003c\/p\u003e\n\u003cp\u003eThe projection utilizes the FY2024 net loss of $26.9 million to estimate a weekly cash burn rate of approximately $517,308 ($\\text{26,900,000} \/ \\text{52 weeks}$). The projection basis starts with the $18.4 million raised through financing activities.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eWeek\u003c\/th\u003e\n\u003cth\u003eStarting Cash Balance (USD)\u003c\/th\u003e\n\u003cth\u003eEstimated Weekly Cash Outflow (USD)\u003c\/th\u003e\n\u003cth\u003eEnding Cash Balance (USD)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 1\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e18,400,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e517,308\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e17,882,692\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 2\u003c\/td\u003e\n\u003ctd\u003e17,882,692\u003c\/td\u003e\n\u003ctd\u003e517,308\u003c\/td\u003e\n\u003ctd\u003e17,365,384\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 3\u003c\/td\u003e\n\u003ctd\u003e17,365,384\u003c\/td\u003e\n\u003ctd\u003e517,308\u003c\/td\u003e\n\u003ctd\u003e16,848,076\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 4\u003c\/td\u003e\n\u003ctd\u003e16,848,076\u003c\/td\u003e\n\u003ctd\u003e517,308\u003c\/td\u003e\n\u003ctd\u003e16,330,768\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 5\u003c\/td\u003e\n\u003ctd\u003e16,330,768\u003c\/td\u003e\n\u003ctd\u003e517,308\u003c\/td\u003e\n\u003ctd\u003e15,813,460\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 6\u003c\/td\u003e\n\u003ctd\u003e15,813,460\u003c\/td\u003e\n\u003ctd\u003e517,308\u003c\/td\u003e\n\u003ctd\u003e15,296,152\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 7\u003c\/td\u003e\n\u003ctd\u003e15,296,152\u003c\/td\u003e\n\u003ctd\u003e517,308\u003c\/td\u003e\n\u003ctd\u003e14,778,844\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 8\u003c\/td\u003e\n\u003ctd\u003e14,778,844\u003c\/td\u003e\n\u003ctd\u003e517,308\u003c\/td\u003e\n\u003ctd\u003e14,261,536\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 9\u003c\/td\u003e\n\u003ctd\u003e14,261,536\u003c\/td\u003e\n\u003ctd\u003e517,308\u003c\/td\u003e\n\u003ctd\u003e13,744,228\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 10\u003c\/td\u003e\n\u003ctd\u003e13,744,228\u003c\/td\u003e\n\u003ctd\u003e517,308\u003c\/td\u003e\n\u003ctd\u003e13,226,920\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 11\u003c\/td\u003e\n\u003ctd\u003e13,226,920\u003c\/td\u003e\n\u003ctd\u003e517,308\u003c\/td\u003e\n\u003ctd\u003e12,709,612\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 12\u003c\/td\u003e\n\u003ctd\u003e12,709,612\u003c\/td\u003e\n\u003ctd\u003e517,308\u003c\/td\u003e\n\u003ctd\u003e12,192,304\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 13\u003c\/td\u003e\n\u003ctd\u003e12,192,304\u003c\/td\u003e\n\u003ctd\u003e517,308\u003c\/td\u003e\n\u003ctd\u003e11,674,996\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe projected remaining cash after 13 weeks, based on the FY2024 net loss burn rate, is approximately $11,674,996.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516195365013,"sku":"krbp-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/krbp-vrio-analysis.png?v=1740188695","url":"https:\/\/dcf-model.com\/pt\/products\/krbp-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}